TY - JOUR
T1 - Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma
T2 - Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi
AU - Merli, Francesco
AU - Luminari, Stefano
AU - Rossi, Giuseppe
AU - Mammi, Caterina
AU - Marcheselli, Luigi
AU - Tucci, Alessandra
AU - Ilariucci, Fiorella
AU - Chiappella, Annalisa
AU - Musso, Maurizio
AU - Rocco, Alice Di
AU - Stelitano, Caterina
AU - Alvarez, Isabel
AU - Baldini, Luca
AU - Mazza, Patrizio
AU - Salvi, Flavia
AU - Arcari, Annalisa
AU - Fragasso, Alberto
AU - Gobbi, Paolo G.
AU - Liberati, Anna Marina
AU - Federico, Massimo
PY - 2012/4
Y1 - 2012/4
N2 - We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the treatment of "fit" elderly patients with diffuse large B-cell lymphoma (DLBCL). Patients over the age of 65 with stage IIIV DLBCL were screened with a comprehensive geriatric assessment. Patients were randomized to receive six courses of R-miniCEOP (n = 114) or R-CHOP (n = 110). Overall, the rate of complete remission was 70% (p = 0.466). After a median follow-up of 42 months, 5-year event-free survival (EFS) rates were 46% and 48% for R-miniCEOP and R-CHOP, respectively (p = 0.538). Patients older than 72 years and with low-risk disease had a better outcome when treated with R-miniCEOP (p = 0.011). Overall R-CHOP and R-miniCEOP are similarly effective for elderly "fit" patients with DLBCL. The less intense R-miniCEOP may be an acceptable option for the treatment of relatively older patients with low-risk disease.
AB - We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the treatment of "fit" elderly patients with diffuse large B-cell lymphoma (DLBCL). Patients over the age of 65 with stage IIIV DLBCL were screened with a comprehensive geriatric assessment. Patients were randomized to receive six courses of R-miniCEOP (n = 114) or R-CHOP (n = 110). Overall, the rate of complete remission was 70% (p = 0.466). After a median follow-up of 42 months, 5-year event-free survival (EFS) rates were 46% and 48% for R-miniCEOP and R-CHOP, respectively (p = 0.538). Patients older than 72 years and with low-risk disease had a better outcome when treated with R-miniCEOP (p = 0.011). Overall R-CHOP and R-miniCEOP are similarly effective for elderly "fit" patients with DLBCL. The less intense R-miniCEOP may be an acceptable option for the treatment of relatively older patients with low-risk disease.
KW - Diffuse large B-cell lymphoma
KW - Elderly
KW - Fit patients
KW - R-CHOP
KW - R-miniCEOP
UR - http://www.scopus.com/inward/record.url?scp=84859094786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859094786&partnerID=8YFLogxK
U2 - 10.3109/10428194.2011.621565
DO - 10.3109/10428194.2011.621565
M3 - Article
C2 - 21895543
AN - SCOPUS:84859094786
VL - 53
SP - 581
EP - 588
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 4
ER -